In this context, the EPH/ephrin system seems to represent an achievable and most promising target for anti-LC treatment, and numerous research groups have already outlined the feasibility of EPH/ephrin targeting in other cancer entities [12,15,16,18]. This evidence concerns the gene EPHA1 and cancer.